Does the media favor ADPT or CYTK?

In the previous week, Cytokinetics had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Cytokinetics' score of 0.12 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cytokinetics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KRYS or ADPT?

In the previous week, Krystal Biotech had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Krystal Biotech and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Krystal Biotech's score of 0.58 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ADPT or NUVL?

In the previous week, Nuvalent had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Nuvalent and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Nuvalent's score of 0.03 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nuvalent 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer IBRX or ADPT?

In the previous week, ImmunityBio had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for ImmunityBio and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat ImmunityBio's score of -0.19 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Adaptive Biotechnologies 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Adaptive Biotechnologies (ADPT) Competitors

$16.90 -1.18 (-6.53%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$17.40 +0.50 (+2.93%)

As of 06/5/2026 07:51 PM Eastern

Compare

ADPT vs. PRAX, CYTK, KRYS, NUVL, and IBRX

Should you buy Adaptive Biotechnologies stock or one of its competitors? MarketBeat compares Adaptive Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adaptive Biotechnologies include Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), Nuvalent (NUVL), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Adaptive Biotechnologies compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Praxis Precision Medicines presently has a consensus price target of $572.72, indicating a potential upside of 125.48%. Adaptive Biotechnologies has a consensus price target of $19.57, indicating a potential upside of 15.81%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Praxis Precision Medicines has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Adaptive Biotechnologies has higher revenue and earnings than Praxis Precision Medicines. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	828.25	-$303.27M	-$13.37	N/A
Adaptive Biotechnologies	$276.98M	9.76	-$59.50M	-$0.33	N/A

In the previous week, Praxis Precision Medicines had 20 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Praxis Precision Medicines' score of -0.08 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Praxis Precision Medicines beats Adaptive Biotechnologies on 9 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Cytokinetics?

Adaptive Biotechnologies (NASDAQ:ADPT) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Adaptive Biotechnologies has higher revenue and earnings than Cytokinetics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	9.76	-$59.50M	-$0.33	N/A
Cytokinetics	$88.04M	101.03	-$784.96M	-$6.84	N/A

Adaptive Biotechnologies has a net margin of -16.82% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Cytokinetics	-784.02%	N/A	-52.86%

Adaptive Biotechnologies has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Adaptive Biotechnologies presently has a consensus target price of $19.57, suggesting a potential upside of 15.81%. Cytokinetics has a consensus target price of $99.30, suggesting a potential upside of 38.92%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cytokinetics had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Cytokinetics' score of 0.12 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cytokinetics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Adaptive Biotechnologies beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Krystal Biotech has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	22.80	$204.83M	$7.48	40.24
Adaptive Biotechnologies	$276.98M	9.76	-$59.50M	-$0.33	N/A

Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Krystal Biotech presently has a consensus target price of $324.11, indicating a potential upside of 7.68%. Adaptive Biotechnologies has a consensus target price of $19.57, indicating a potential upside of 15.81%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Krystal Biotech has a net margin of 53.92% compared to Adaptive Biotechnologies' net margin of -16.82%. Krystal Biotech's return on equity of 19.25% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Krystal Biotech had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Krystal Biotech and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Krystal Biotech's score of 0.58 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Krystal Biotech beats Adaptive Biotechnologies on 12 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Nuvalent?

Adaptive Biotechnologies (NASDAQ:ADPT) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, Nuvalent had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Nuvalent and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Nuvalent's score of 0.03 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nuvalent	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Adaptive Biotechnologies presently has a consensus target price of $19.57, suggesting a potential upside of 15.81%. Nuvalent has a consensus target price of $141.24, suggesting a potential upside of 55.29%. Given Nuvalent's stronger consensus rating and higher possible upside, analysts clearly believe Nuvalent is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Adaptive Biotechnologies has higher revenue and earnings than Nuvalent. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	9.76	-$59.50M	-$0.33	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Adaptive Biotechnologies has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Nuvalent has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Nuvalent	N/A	-40.11%	-35.43%

Summary

Adaptive Biotechnologies beats Nuvalent on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, ImmunityBio had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for ImmunityBio and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat ImmunityBio's score of -0.19 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 105.20%. Adaptive Biotechnologies has a consensus price target of $19.57, suggesting a potential upside of 15.81%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Adaptive Biotechnologies has higher revenue and earnings than ImmunityBio. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	63.97	-$351.40M	-$0.85	N/A
Adaptive Biotechnologies	$276.98M	9.76	-$59.50M	-$0.33	N/A

Adaptive Biotechnologies has a net margin of -16.82% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Summary

Adaptive Biotechnologies beats ImmunityBio on 8 of the 15 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.70B	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.56%
P/E Ratio	-51.21	18.69	24.03	23.62
Price / Sales	9.76	300.27	513.89	111.51
Price / Cash	N/A	51.45	26.99	37.22
Price / Book	11.50	7.97	10.24	6.66
Net Income	-$59.50M	$23.89M	$3.57B	$337.55M
7 Day Performance	11.55%	-6.96%	-1.28%	-2.52%
1 Month Performance	15.04%	-2.80%	1.38%	-0.03%
1 Year Performance	67.49%	36.80%	23.93%	25.34%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	3.0649 of 5 stars	$16.90 -6.5%	$19.57 +15.8%	+67.5%	$2.70B	$276.98M	N/A	790	News Coverage Positive News
PRAX Praxis Precision Medicines	2.8606 of 5 stars	$335.16 -4.2%	$592.67 +76.8%	+470.0%	$9.34B	N/A	N/A	110	News Coverage Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.8552 of 5 stars	$73.68 -4.0%	$99.30 +34.8%	+121.3%	$9.17B	$105.82M	N/A	250
KRYS Krystal Biotech	3.0415 of 5 stars	$298.10 -3.5%	$324.11 +8.7%	+119.8%	$9.11B	$417.30M	39.85	210	News Coverage Insider Trade
NUVL Nuvalent	3.4627 of 5 stars	$93.01 -15.7%	$140.29 +50.8%	+16.6%	$8.72B	N/A	N/A	40	Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Adaptive Biotechnologies compare to Praxis Precision Medicines?

Summary

How does Adaptive Biotechnologies compare to Cytokinetics?

Summary

How does Adaptive Biotechnologies compare to Krystal Biotech?

Summary

How does Adaptive Biotechnologies compare to Nuvalent?

Summary

How does Adaptive Biotechnologies compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. PRAX, CYTK, KRYS, NUVL, and IBRX

How does Adaptive Biotechnologies compare to Praxis Precision Medicines?

Do analysts rate PRAX or ADPT?

Is PRAX or ADPT more profitable?

Which has more volatility & risk, PRAX or ADPT?

Do insiders and institutionals have more ownership in PRAX or ADPT?

Which has higher earnings and valuation, PRAX or ADPT?

Does the media prefer PRAX or ADPT?

Summary

How does Adaptive Biotechnologies compare to Cytokinetics?

Which has better valuation and earnings, ADPT or CYTK?

Is ADPT or CYTK more profitable?

Which has more volatility & risk, ADPT or CYTK?

Do analysts recommend ADPT or CYTK?

Do institutionals and insiders hold more shares of ADPT or CYTK?

Does the media favor ADPT or CYTK?

Summary

How does Adaptive Biotechnologies compare to Krystal Biotech?

Which has stronger valuation & earnings, KRYS or ADPT?

Which has more risk and volatility, KRYS or ADPT?

Do analysts recommend KRYS or ADPT?

Is KRYS or ADPT more profitable?

Do institutionals & insiders believe in KRYS or ADPT?

Does the media refer more to KRYS or ADPT?

Summary

How does Adaptive Biotechnologies compare to Nuvalent?

Does the media favor ADPT or NUVL?

Do analysts recommend ADPT or NUVL?

Do institutionals and insiders hold more shares of ADPT or NUVL?

Which has preferable valuation & earnings, ADPT or NUVL?

Which has more volatility and risk, ADPT or NUVL?

Is ADPT or NUVL more profitable?

Summary

How does Adaptive Biotechnologies compare to ImmunityBio?

Do institutionals & insiders hold more shares of IBRX or ADPT?

Does the media prefer IBRX or ADPT?

Which has more volatility & risk, IBRX or ADPT?

Do analysts recommend IBRX or ADPT?

Which has higher earnings and valuation, IBRX or ADPT?

Is IBRX or ADPT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools